New insights into the role of T cells in the vicious cycle of bone metastases

Pierrick G.J. Fournier, John M. Chirgwin, Theresa A. Guise

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Bone metastases interact with the bone microenvironment. Cancer cells modulate the functions of osteoblasts and osteoclasts to induce new bone formation or bone resorption, leading to secondary stimulation of tumor development. Recent findings suggest the involvement of T cells in this process. RECENT FINDINGS: Bone metastatic cancer cells produce factors such as parathyroid hormone-related protein, interleukin-7, and interleukin-8 that can recruit or activate T cells. T cells are involved in bone remodeling and can induce osteoclastic resorption. Bone resorption releases transforming growth factor-β, however, which could suppress T-cell antitumor immune responses. Bisphosphonate antiresorptive drugs are the approved treatment for solid tumor bone metastases. They have recently been found to activate the cytolytic activity of γδ T cells. Thus, inhibitors of transforming growth factor-β or antiresorptive therapies may be effective enhancers of antitumor immune responses in bone. SUMMARY: T cells at the site of bone metastases may be functionally suppressed by factors in the bone microenvironment. Instead of acting against tumor cells, they may increase bone resorption, making bone a privileged site for tumor growth.

Original languageEnglish (US)
Pages (from-to)396-404
Number of pages9
JournalCurrent Opinion in Rheumatology
Volume18
Issue number4
DOIs
StatePublished - Jul 1 2006

Fingerprint

Neoplasm Metastasis
T-Lymphocytes
Bone and Bones
Bone Resorption
Transforming Growth Factors
Neoplasms
Bone Density Conservation Agents
Parathyroid Hormone-Related Protein
Interleukin-7
Bone Neoplasms
Bone Remodeling
Diphosphonates
Osteoclasts
Osteoblasts
Interleukin-8
Osteogenesis
Growth

Keywords

  • Bisphosphonate
  • Bone metastases
  • Multiple myeloma
  • T cells
  • Transforming growth factor-β

ASJC Scopus subject areas

  • Rheumatology

Cite this

New insights into the role of T cells in the vicious cycle of bone metastases. / Fournier, Pierrick G.J.; Chirgwin, John M.; Guise, Theresa A.

In: Current Opinion in Rheumatology, Vol. 18, No. 4, 01.07.2006, p. 396-404.

Research output: Contribution to journalReview article

@article{b5e1dcffda3d4370bc3f44868c72e914,
title = "New insights into the role of T cells in the vicious cycle of bone metastases",
abstract = "PURPOSE OF REVIEW: Bone metastases interact with the bone microenvironment. Cancer cells modulate the functions of osteoblasts and osteoclasts to induce new bone formation or bone resorption, leading to secondary stimulation of tumor development. Recent findings suggest the involvement of T cells in this process. RECENT FINDINGS: Bone metastatic cancer cells produce factors such as parathyroid hormone-related protein, interleukin-7, and interleukin-8 that can recruit or activate T cells. T cells are involved in bone remodeling and can induce osteoclastic resorption. Bone resorption releases transforming growth factor-β, however, which could suppress T-cell antitumor immune responses. Bisphosphonate antiresorptive drugs are the approved treatment for solid tumor bone metastases. They have recently been found to activate the cytolytic activity of γδ T cells. Thus, inhibitors of transforming growth factor-β or antiresorptive therapies may be effective enhancers of antitumor immune responses in bone. SUMMARY: T cells at the site of bone metastases may be functionally suppressed by factors in the bone microenvironment. Instead of acting against tumor cells, they may increase bone resorption, making bone a privileged site for tumor growth.",
keywords = "Bisphosphonate, Bone metastases, Multiple myeloma, T cells, Transforming growth factor-β",
author = "Fournier, {Pierrick G.J.} and Chirgwin, {John M.} and Guise, {Theresa A.}",
year = "2006",
month = "7",
day = "1",
doi = "10.1097/01.bor.0000231909.35043.da",
language = "English (US)",
volume = "18",
pages = "396--404",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - New insights into the role of T cells in the vicious cycle of bone metastases

AU - Fournier, Pierrick G.J.

AU - Chirgwin, John M.

AU - Guise, Theresa A.

PY - 2006/7/1

Y1 - 2006/7/1

N2 - PURPOSE OF REVIEW: Bone metastases interact with the bone microenvironment. Cancer cells modulate the functions of osteoblasts and osteoclasts to induce new bone formation or bone resorption, leading to secondary stimulation of tumor development. Recent findings suggest the involvement of T cells in this process. RECENT FINDINGS: Bone metastatic cancer cells produce factors such as parathyroid hormone-related protein, interleukin-7, and interleukin-8 that can recruit or activate T cells. T cells are involved in bone remodeling and can induce osteoclastic resorption. Bone resorption releases transforming growth factor-β, however, which could suppress T-cell antitumor immune responses. Bisphosphonate antiresorptive drugs are the approved treatment for solid tumor bone metastases. They have recently been found to activate the cytolytic activity of γδ T cells. Thus, inhibitors of transforming growth factor-β or antiresorptive therapies may be effective enhancers of antitumor immune responses in bone. SUMMARY: T cells at the site of bone metastases may be functionally suppressed by factors in the bone microenvironment. Instead of acting against tumor cells, they may increase bone resorption, making bone a privileged site for tumor growth.

AB - PURPOSE OF REVIEW: Bone metastases interact with the bone microenvironment. Cancer cells modulate the functions of osteoblasts and osteoclasts to induce new bone formation or bone resorption, leading to secondary stimulation of tumor development. Recent findings suggest the involvement of T cells in this process. RECENT FINDINGS: Bone metastatic cancer cells produce factors such as parathyroid hormone-related protein, interleukin-7, and interleukin-8 that can recruit or activate T cells. T cells are involved in bone remodeling and can induce osteoclastic resorption. Bone resorption releases transforming growth factor-β, however, which could suppress T-cell antitumor immune responses. Bisphosphonate antiresorptive drugs are the approved treatment for solid tumor bone metastases. They have recently been found to activate the cytolytic activity of γδ T cells. Thus, inhibitors of transforming growth factor-β or antiresorptive therapies may be effective enhancers of antitumor immune responses in bone. SUMMARY: T cells at the site of bone metastases may be functionally suppressed by factors in the bone microenvironment. Instead of acting against tumor cells, they may increase bone resorption, making bone a privileged site for tumor growth.

KW - Bisphosphonate

KW - Bone metastases

KW - Multiple myeloma

KW - T cells

KW - Transforming growth factor-β

UR - http://www.scopus.com/inward/record.url?scp=33748080768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748080768&partnerID=8YFLogxK

U2 - 10.1097/01.bor.0000231909.35043.da

DO - 10.1097/01.bor.0000231909.35043.da

M3 - Review article

C2 - 16763461

AN - SCOPUS:33748080768

VL - 18

SP - 396

EP - 404

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 4

ER -